This move is archived. Current quotes and coverage live on the stock page.
Get BLCO alerts:
Bausch + Lomb Corp's stock took a hit today, closing down 2.04% as investors react to recent developments.
In the latest trading session, Bausch + Lomb Corp (BLCO.TO) experienced a decline of 2.04%, closing at CA$20.61. This drop comes amid ongoing concerns about the company's financial performance and recent strategic moves.
Advertisement
Bausch + Lomb Corp
BLCO.TO
BLCO.TO
Bausch + Lomb Corp
WealthAwesomeMarket cap
$8.87B
52W high
$25.70
52W low
$19.36
1W change
+5.17%
Beta
0.55
Analyst Price Targets
Based on analyst covering BLCO
Wall Street analysts forecast BLCO stock price to rise 1.0% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$25.07
+1.0% Upside
Current Price
C$24.83
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BLCO's historical volatility
30-Day Vol
21.8%
Annualized
90-Day Vol
27.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$29.68
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$26.35 | C$24.45 โ C$28.41 |
| 60 trading days | C$27.97 | C$25.15 โ C$31.10 |
| 90 trading days | C$29.68 | C$26.07 โ C$33.81 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor Bausch + Lomb's financial health and strategic initiatives as the company navigates challenges in the ophthalmic market.
Bausch + Lomb Corp's stock down 2.04% today
With a market cap of approximately CA$7.5 billion, Bausch + Lomb's recent performance reflects investor caution amid financial uncertainties.
Bull case
Bausch + Lomb's investment in Emmecell's innovative magnetic cell delivery technology could set the stage for future growth in the ophthalmic sector. This technology addresses significant clinical needs and could enhance the company's offerings.
Bear case
The company's current negative profit margin and lack of a dividend yield raise concerns about its financial stability and ability to generate returns for shareholders.
Advertisement
Recent Performance and Market Reaction
Bausch + Lomb's stock decline of 2.04% reflects investor sentiment amid concerns about the company's financial health. With a market cap nearing CA$7.5 billion, the stock's performance is indicative of broader market apprehensions regarding profitability and growth potential.
Strategic Moves and Future Outlook
The company's recent investment in Emmecell, aimed at advancing innovative treatment options for ophthalmic diseases, could provide a pathway for future growth. However, the lack of profitability and dividend yield raises questions about the sustainability of such investments. Investors should keep an eye on how these strategic moves unfold in the coming quarters. For more insights, check out our detailed analysis on Bausch + Lomb Corp.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
